SCHEMBL319970

SCHEMBL319970

Nc1[nH]ncc1-c1cc(F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl

nearest known ligand 0.88

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 20/20 0.88
CYP2C9 P11712 2/20 0.88
SCN5A Q14524 2/20 0.88
SCN2B O60939 1/20 0.88
SCN1A P35498 1/20 0.88
SCN4A P35499 1/20 0.88
SCN7A Q01118 1/20 0.88
SCN1B Q07699 1/20 0.88
SLC22A12 Q96S37 1/20 0.88
SCN2A Q99250 1/20 0.88
SCN3A Q9NY46 1/20 0.88
SCN8A Q9UQD0 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL14889980 0.94 SCN9A (0.79) SCN9ACYP2C9SCN5ASCN2BSCN1A
Pf-05089771 SCHEMBL31060533 0.93 SCN9A (1.00) SCN9ACYP2C9SCN5ASCN2BSCN1A
Pf-05089771 SCHEMBL1095065 0.93 SCN9A (1.00) SCN9ACYP2C9SCN5ASCN2BSCN1A
Pf-05089771 SCHEMBL29376793 0.93 SCN9A (1.00) SCN9ACYP2C9SCN5ASCN2BSCN1A
SCHEMBL17450366 0.91 SCN9A (1.00) SCN9ACYP2C9SCN5ASCN2BSCN1A
SCHEMBL321513 0.88 SCN9A (0.89) SCN9ACYP2C9SCN5ASCN2BSCN1A
SCHEMBL9924611 0.85 SCN9A (0.85) SCN9ACYP2C9SCN5ASCN2BSCN1A
Pf-05089771 SCHEMBL14880153 0.85 SCN9A (0.84) SCN9ACYP2C9SCN5ASCN2BSCN1A
SCHEMBL16531041 0.85 SCN9A (1.00) SCN9ACYP2C9SCN5ASCN2BSCN1A
SCHEMBL16001939 0.84 SCN9A (0.72) SCN9ACYP2C9SCN5ASCN2BSCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US claimed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP claimed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP claimed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US claimed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO claimed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B SCN9A 11/4885CYP2C9 492/4885SCN5A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.